U.S. health advisors are debating whether kid-size doses of Pfizer's COVID-19 vaccine are safe and effective in young children ages 5 to 11.
Kid-size doses of the COVID-19 vaccine made by Pfizer and BioNTech may be getting closer as government advisors on Tuesday began deliberating whether there’s enough evidence that the shots are safe and effective for children ages 5 to 11.
A study of elementary schoolchildren found the Pfizer shots were nearly 91% effective at preventing coronavirus infections with COVID-19 symptoms — even though the youngsters received just a third of the dose given to teens and adults. In a preliminary analysis last week, reviewers at the Food and Drug Administration said that protection would “clearly outweigh” the risk of a very rare side effect in almost all scenarios of the pandemic. Now members of the FDA’s scientific advisory panel are combing through the data to see if they agree.
If the FDA authorizes the kid-size doses, there are still more steps ahead: Next week, the Centers for Disease Control and Prevention will have to decide whether to recommend the shots, and if so, which youngsters should get them.Although children are at lower risk of severe COVID-19 than older people, 5- to 11-year-olds still have faced substantial illness — including more than 8,300 hospitalizations.
“I want to acknowledge the fact that there are strong feelings” among the public for and against child vaccinations, Marks added, noting that the discussion would be on scientific data, “not about vaccine mandates, which are left to other entities outside of FDA.”
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Fresh lockdowns in China as local Covid-19 infections spread to 11 provincesAuthorities in northern China are reimposing lockdowns and other emergency measures to curb the spread of coronavirus, with health officials warning of a worsening outbreak after the country recorded more than 100 cases across 11 provinces over the last week.
続きを読む »
Moderna says its COVID-19 vaccine is protective, safe in kids 6 to 11Moderna said its two-dose vaccine generated virus-neutralizing antibodies in children and safety was comparable to what was previously seen in clinical trials of adolescents and adults.
続きを読む »
Moderna Says Its Low-Dose COVID-19 Vaccine Works For Kids 6 To 11Children who received the vaccine developed virus-fighting antibodies similar to levels that young adults produce after full-strength shots, Moderna said.
続きを読む »
Moderna Data Shows Covid-19 Vaccine Produced Strong Immune Response in 6- to 11-Year-OldsModerna said it would submit the results from an interim study to health regulators in the U.S., Europe and elsewhere in seeking authorization for 6- to 11-year-olds.
続きを読む »
Pfizer CEO says company will produce 4 billion COVID-19 doses in 2022Pfizer CEO Albert Bourla says the company is increasing its output to meet global demand.
続きを読む »
COVID-19 live updates: FDA panel hours away from vote on Pfizer vaccine for kidsAn independent FDA advisory panel will debate and vote on whether to authorize the Pfizer vaccine for children ages 5 to 11. The nonbinding vote is expected between 4:30 p.m. and 5 p.m. ET today.
続きを読む »